InterAx Overview
- Status
-
Private
- Employees
-
17

- Latest Deal Type
-
Later Stage VC
- Investors
-
11
InterAx General Information
Description
Developer of a drug discovery platform created to reduce the time and costs for the discovery and development of new drugs for a wide array of human diseases. The company combines artificial intelligence, mathematical models of signaling pathways, cellular assays, and computational chemistry enabling it to cover signaling response characterization and optimization where it uniquely takes into account cellular background effects (system bias) as well as experimental assays amplification effects and temporal effects (observation bias) with proprietary mathematical models.
Contact Information
- Park Innovaare
- 5234 Villigen
- Switzerland
InterAx Timeline
InterAx Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
8. Later Stage VC | 01-Nov-2022 | 00.000 | Completed | Pre-Clinical Trials | ||
7. Grant | 25-Nov-2019 | 00.000 | 00.000 | Completed | Pre-Clinical Trials | |
6. Accelerator/Incubator | 11-Oct-2019 | 00.000 | 00.000 | Completed | Pre-Clinical Trials | |
5. Seed Round | 15-Jan-2019 | 00.000 | 00.000 | 000.00 | Completed | Pre-Clinical Trials |
4. Seed Round | 23-Dec-2016 | 00000 | Completed | Startup | ||
3. Grant | 21-Oct-2016 | 000.00 | 00000 | Completed | Startup | |
2. Accelerator/Incubator | 01-Jan-2016 | $130K | $130K | Completed | Startup | |
1. Grant | 01-Aug-2014 | $167K | Completed | Startup |
InterAx Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
InterAx Comparisons
Industry
Financing
Details
InterAx Competitors (41)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Exscientia | Formerly VC-backed | Oxford, United Kingdom | 000 | 00000 | 000000000 | 00000 |
00000000 000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 00000000 | |
00000 000000000000 | Formerly VC-backed | Cambridge, United Kingdom | 00 | 00000 | 000000&0 | 00000 |
00000000 | Venture Capital-Backed | San Francisco, CA | 00 | 00000 | 0000000000 | 00000 |
000000 00000000000 | Venture Capital-Backed | Boston, MA | 00 | 00000 | 0000000000 0 | 00000 |
InterAx Patents
InterAx Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3878447-A1 | Beta adrenergic receptor antagonists | Inactive | 11-Mar-2020 | 0000000000 | 0 |
US-20220106382-A1 | Beta-arrestin mutants | Pending | 22-Jan-2019 | 0000000000 | |
JP-7216216-B2 | Beta-arrestin mutant | Active | 22-Jan-2019 | 0000000000 | 0 |
JP-2022518549-A | Beta-arrestin mutant | Active | 22-Jan-2019 | 0000000000 | 0 |
CA-3127255-A1 | Beta-arrestin mutants | Pending | 22-Jan-2019 | C07K14/723 |
InterAx Executive Team (8)
InterAx Board Members (5)
Name | Representing | Role | Since |
---|---|---|---|
Aurélien Rizk Ph.D | InterAx | Co-Founder & Board Member | 000 0000 |
Bettina Ernst Ph.D | Bernina BioInvest | Board Member | 000 0000 |
Jens Gobrecht | Self | Chairman | 000 0000 |
Yiannis Monovoukas Ph.D | Falcon III Ventures | Board Member | 000 0000 |
InterAx Signals
InterAx Investors (11)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Convergence Partners (Switzerland) | Venture Capital | Minority | 000 0000 | 000000 0 | |
Plug and Play Tech Center | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
Horizon 2020 SME Instrument | Government | 000 0000 | 000000 0 | ||
EIC Accelerator | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
Bernina BioInvest | Venture Capital | Minority | 000 0000 | 000000 0 |